FIELD : medicine; pharmaceuticals.SUBSTANCE : invention relates to a compound of formula Ior a pharmaceutically acceptable salt thereof, where Z is or , where X is absent, or X is selected from a group consisting of NH and CH2; R is selected from a group consisting of hydrogen, amino and lower alkyl, R1 is selected from a group consisting of hydrogen and halogen, R2 is hydrogen, R3 and R4 are independently selected from a group consisting of hydrogen, C1-C8 alkyl, (CR5R6)aC(O)OR7, (CR5R6)aOR7, (CR5R6)aC(O)N(R7)2, (CR5R6)aN(R7)2, wherein N(R7)2 can be taken together to form 3–7-member heterocyclic ring optionally substituted with one or more R5, wherein, if one of R3 and R4 is (CR5R6)aC(O)OR7, the other can not be (CR5R6)aC(O)OR7; or R3 and R4 can be taken together with a sulfur atom to form 4–7-member heterocyclic ring optionally substituted with one or more R9, R5 is selected from a group consisting of hydrogen, hydroxy and CH2CH2OCH2CH2OH; R6 is hydrogen; R7 is selected from a group consisting of hydrogen, C1-C8 alkyl, fluorine; R9 is selected from a group consisting of hydrogen, C1-C8 alkyl; Ar1 and Ar2 are independently selected from a group consisting of, , , , , , where R8 is selected from a group consisting of hydrogen, C1-C4 alkyl, amino, hydroxyl, alkoxy, halogen and CF3, and equals 0 or integer from 1 to 4.EFFECT : compounds are able to modulate the tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.19 cl, 10 tbl, 42 ex